New challenges in the treatment of epilepsy

Saudi Medical Journal

Volumn 17, Issue 4, 1996, Pages 428-436

  Deleu, Dirk ^a   Hanssens, Yolande ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

anticonvulsants; epilepsy; felbamate; gabapentin; lamotrigine; oxcarbazepin e; progabide; vigabatrin; zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PROGABIDE; VIGABATRIN; ZONISAMIDE;

ALLERGY; APLASTIC ANEMIA; ATAXIA; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DYSARTHRIA; EPILEPSY; HUMAN; LIVER TOXICITY; NEPHROLITHIASIS; RASH; REVIEW; TREMOR;

EID: 0029807292     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Annegers JF, Hauser WA, Elverbak LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979; 20: 729-737.
2. Fisher RS. Emerging antiepileptic drugs. Neurology 1993; 43 (suppl 5): S12-S20.
3. Plug CB, Garnell WR. Current issues in the treatment of epilepsy. Clin Pharm 1991; 10: 335-358.
4. Sofia RD, Kramer L, Perhach JL, et al. Felbamate. Epilepsy Res 1991; 3 (suppl 3): 103-108.
5. Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986; 27: 27-34.
6. Wagner ML. Felbamate: A new antiepileptic drug. Am J Hosp Pharm 1994; 51: 1657-1666.
7. Graves NM, Holmes GB, Fuerst RH, et al. Effect of felbamate on phenytoin and carbamazepine serum concentrations, Epilepsia 1989; 30: 225-229.
8. Wagner ML, Graves NM, Leppik, IE, et al The effect of felbamate on valproate disposition [abstract]. Epilepsia 1991; 32: 15.
9. Wagner ML, Graves NM, Marienau K, Holmes GB, Remmel RP, Leppik IE. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 1991; 32: 398-406.
10. Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995; 45: 456-460.
11. Acute liver failure linked to felbamate use [editorial]. Am J Hosp Pharm 1994; 51: 2882-2887.
12. Chadwick D. Gabapentin. Epilepsy Res 1991; 3 (suppl): 183-186.
13. Taylor CP, Vartanian MG, Yuen P-W, Bigge C, Suman Chauhan N, Hill DR. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA related to in vitro binding at a novel site labelled by tritiated gabapentin. Epilepsy Res 1992; 14: 11-15.
14. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335: 1114-1117.
15. Goa KL, Sorkin EM. Gabapentin. Drugs 1993; 46: 409-427.
16. Browne TR. Efficacy and safety of gabapentin. In: Chadwick D. Editor. London: Royal Society of Medicine Services Ltd, 1993: 45-47.
17. Leach MJ, Harden CM, Miller AA. Pharmacological studies of lamotrigine, a novel potential antiepileptic drug, II: neurochemical studies on the mechanism of action. Epilepsia 1986; 27: 490-497.
18. Brodie MJ, Richens A, Yen AWC, for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-479.
19. Yuen AWC. Lamotrigine. In: Pisani F, Perucca E, Avanzini G, Richens A, eds. New antiepileplic drugs (Epilepsy Res Suppl). Amsterdam: Elsevier Science Publishers BV, 1991: 115-123.
20. Timmins PL, Richens A. Efficacy of lamotrigine as monotherapy for juvenile myoclonic epilepsy [abstract]. Epilepsia 1993; 34 (suppl 2): 160.
21. Brodie MJ. Lamotrigine. Lancet 1992; 339: 1397-1400.
22. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 1991; 32 (suppl 2): S9-S12.
23. Dam M, Ekberg R, Loyning Y, et al., and the Scandinavian Oxcarbazepine Study Group. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-76.
24. Feldmann KF, Brechbuhler S, Faigle JW, Imhof P. Pharmacokinetics and metabolism of GP 47 680, a compound related to carbamazepine in animals and man. In: Meinardi H, Rowan AJ, eds. Advances in epileptology. Amsterdam: Swets and Zeitlinger, 1978: 290-294.
25. Pendlebury SC, Moses DK, Eadie MJ. Hyponatremia during oxcarbazepine therapy. Hum Toxicol 1989; 8: 337-344.
26. Morselli PM, Bartholini G, Lloyd KG. Progabide. In: Meldrum BS, Porter RJ eds. New Anticonvulsant Drugs. London: John Libbey, 1986: 237-253.
27. Leppik IE, Dreifuss FE, Porter R, et al. A controlled study of progabide in partial seizures: Methodology and results. Neurology 1987; 37: 963-968.
28. Schmidt D, Utech K. Progabide for refractory partial epilepsy: A controlled add-on trial. Neurology 1986; 36: 217-221.
29. Gerstle de Pasquet E, Scaramelli A, Piñeyrúa de Cáceres, et al. Double-blind, placebo controlled, cross-over trial of progabide as add-on therapy in epileptic patients. Epilepsia 1991; 32: 133-139.
30. Crawford P, Chadwick D. A comparative study of progabide, valproate. and placebo as add-on therapy in patients with refractory epilepsy. J. Neurol Neurosurg Psychiatry 1986; 49: 1251-1257.
31. Bianchetti G, Padovani P, Thenot JP, Thiercelin JF, Morselli PL. Pharmacokinetic interactions of progabide with other antiepileptic drugs. Epilepsia 1987: 28: 68-73.
32. Schechter PJ, Hanke NFJ, Grove J, et al. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology 1984; 34: 182-186.
33. Livingston JH, Beaumont D, Arzimanoglou A, et al. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol 1989; 27: 109S-112S.
34. Rey E, Pons G, Olive G. Vigabatrin: clinical pharmacokineties. Clin Pharmacokinet 1992: 23: 267-278.
35. Richens A. Potential antiepileptic drugs: vigabatrin. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE, eds. Antiepileptic drugs, 3rd edition. New York: Raven Press. 1989: 937-946.
36. Browne TR, Mattson R, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicentre single blind study with long term follow-up. Neurology 1987; 37: 184-189.
37. Ring HA, Trimble MR, Costa DC, George MS, Verhoeff P, Ell PJ. Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems. J Neurol Neurosurg Psychiatry 1992; 55: 758-761.
38. Sander JWAS, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991; 54: 435-439.
39. Seino M, Miyazaki H, Ito T. Zonisamide. In: Pisani F, Perucca E, Avanzini G, Richens A, eds. New antiepileptic drugs (Epilepsy Res Suppl). Amsterdam: Elsevier Science Publishers BV, 1991: 169-174.
40. Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy. Drugs 1993; 45: 760-787.
41. Sackellares JC, Donofrio PD, Wagner JG, et al. Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia 1985; 26: 206-221.
42. Thakker KM, Mangat S, Garnett WR, et al. Comparative bioavailability and steady state fluctuations of Tegretol commercial and cabamazepine oros tablets in adult and pediatric epileptic patients. Biopharm Drug Dispos 1992; 13: 559-569.